Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-CXCR4R334X NK cells
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-CXCR4R334X NK cells are a genetically engineered natural killer (NK) cell therapy designed to treat multiple myeloma. These NK cells are modified to express a chimeric antigen receptor (CAR) that targets B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells in multiple myeloma. Additionally, they are engineered to express a mutant CXCR4 receptor (CXCR4^R334X), which enhances the cells' homing and migration toward the bone marrow microenvironment by increasing responsiveness to the chemokine CXCL12/SDF-1α. This modification boosts bone marrow infiltration, in situ activation, and the cytolytic function of NK cells against BCMA-positive tumor cells. Preclinical studies indicate increased anti-myeloma efficacy compared to unmodified or standard BCMA-CAR NK cells. The key mechanistic advantage is enhanced tumor site localization, cytotoxic response, and improved CAR signaling independent of external CXCL12 stimulation.
- Other names
- BCMA CAR-NK-CXCR4R334X cells
02
Targets
BCMA (B-cell maturation antigen)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on BCMA CAR-CXCR4R334X NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-CXCR4R334X NK cells.